Searchable abstracts of presentations at key conferences in endocrinology

ea0064026 | An adrenal tumor with gynecomastia | BES2019

An adrenal tumor with gynecomastia

De Herdt C , Philipse E , De Block C

Initial presentation and work-up: A 42-year-old man was referred to the endocrinologist because of an incidentaloma of the right adrenal with a maximum diameter of 4.2 cm on echography of the abdomen. Echography was performed because the patient presented with icterus. An abdominal CT scan confirmed a right adrenal mass with a maximum diameter of 5.1 cm. The intensity of the adrenal adenoma amounted 39 Hounsfield units. The patient did not have a significant medical history, e...

ea0064040 | Prepubertal gynecomastia: what to suspect first? | BES2019

Prepubertal gynecomastia: what to suspect first?

Karolien Van de Maele , Daniel Klink , Jean De Schepper

Introduction: Most cases of prepubertal gynecomastia are classified as idiopathic. However, an exogenous or endogenous hyperestrogenism (from estrogen producing testis or adrenal tumors) has always to be excluded. Other rare underlying endocrine causes are congenital adrenal hyperplasia, aromatase excess, hyperthyroidism and hyperprolactinemia1,2.We report a transient hyperprolactinemia, beside other ignored clinical and hormonal signs of estr...

ea0032p182 | Cardiovascular Endocrinology & Lipid Metabolism | ECE2013

Short-term changes in serum sex steroid levels and cardiac function in healthy young men

De Smet Maarten , Lapauw Bruno , De Backer Tine , Ruige Johannes

Introduction: Male obesity is associated with an increase in estradiol (E2) and a decrease in testosterone (T). And, although sex steroids are associated with cardiovascular disease, direct effects on cardiac structure and function are hardly investigated in humans.Methodology: Twenty healthy men aged 20–40 years were randomized into two groups. One group was given an aromatase inhibitor (letrozole) only, thus obtaining a high testosteron...

ea0028p10 | Bone | SFEBES2012

The use of teriparatide to treat hypoparathyroidism following thyroidectomy; a case report

De Silva Akila , De Silva Sarah-Jane , Meeran Karim

A 27 year old lady with Graves’ thyrotoxicosis (fT4 50.3 pmol/L, fT3 25.0 pmol/L, TSH<0.05 mU/L) failed to respond adequately to carbimazole (40 mg BD) or propylthiouracil (250 mg QDS). Three months later, following 10 days of potassium iodide to render her biochemically euthyroid, she underwent a total thyroidectomy. Pre-operative bone profile revealed Ca(c) 2.34 mmol/L (NR 2.15–2.60 mmol/L), phosphate 1.36 mmol/L (NR 0.8–1.4 mmol/L), PTH 3.4 pmol/L (NR 1.1...

ea0016p801 | Thyroid | ECE2008

TSH levels and thyroid nodules correlation in autoimmune thyroiditis

Vianale Luigi , Remigis Alessandra De , Ranieti Paola , Remigis Pierluigi De

The role of TSH in the pathogenesis of thyroid nodule (TN) is controversial.We have evaluated the prevalence of TN in a group of 800 subjects with and without autoimmune thyroiditis (AT). The prevalence of TN, the number and volume of nodules was evaluated in relation with TSH and antithyroid antibodies titles.The subjects were of both sex, aged between 20 and 80 years and were recruited in a random manner, in the context of an epi...

ea0011s29 | Novel peptides in reproduction | ECE2006

Novel recombinant gonadotropin molecules in human reproductive dysfunction

Mannaerts B , de Haan T , de Greef R

Org 36286 is a sustained follicular stimulant (SFS) inducing multiple follicular development in patients undergoing controlled ovarian stimulation. Due to its long half-life a single dose of Org 36286 may replace the first 7 injections of daily recFSH and after this one week interval, stimulation may be continued with daily recFSH up to the day of triggering ovulation (Org 36286 regimen). Ideally, recFSH should be started as soon as Org 36286 levels become too low to support m...

ea0057028 | A delayed diagnosis of endocrine hypertension | BES2018

A delayed diagnosis of endocrine hypertension

De Herdt C , De Keyser L , Gheuens E

A 43-year old woman was referred to the endocrinologist due to resistant arterial hypertension with a history of bilateral adrenal hypertrophy. The first medical contact with the patient dates back to 2012 when she was admitted to the urology department. A CT scan of the abdomen revealed a bilateral adrenal mass, hypodens lesions in the liver and a small left kidney. Further imaging with MRI showed similar findings. The liver lesions were described as hemangiomas. Because of h...

ea0097013 | Section | BES2023

Acquired idiopathic isolated adrenocorticotropic hormone deficiency: a descriptive systematic review of a heterogeneous and underreported disease

Mieghem E Van , Block C De , Herdt C De

Purpose: Deficiency of the adrenocortical axis is, except for glucocorticoid-induced adrenal deficiency, most commonly associated with failure of multiple pituitary axes and is less common isolated. Isolated adrenocorticotropic hormone deficiency (IAD) has been first described by Steinberg et al. in 1954. Acquired idiopathic IAD is defined by a secondary adrenal insufficiency with otherwise normal pituitary function, absence of structural pituitary defects, no...

ea0097021 | Section | BES2023

A non-controlled Cushing disease treated with osilodrostat: A case report

L Depoorter , Block C De , Herdt C De

Introduction: Cushing disease (CD) is a rare pathology and associated with serious complications and an increased mortality (standardized mortality ratio 2.8) (1). The mortality risk is twice as high (standardized mortality ratio 5.7) if CD is biochemically not well controlled. Transsphenoidal tumor resection is the first line treatment. However, the need for second line treatment is high, as 5-50% of patients in remission after surgery relapse and consist of ...

ea0099p100 | Endocrine-Related Cancer | ECE2024

Incidentaloma on Ga-68-DOTANOC PET; prevalence and clinical significance

De Herdt Carlien , Laura Naert , Sigrid Stroobants , Christophe De Block

Introduction: Over the past years Ga-68-DOTANOC PET/CT is increasingly performed, which may lead to an increase in encountering incidentaloma. In 2022, a systematic review was published about incidentaloma on Ga-68-DOTANOC/DOTATE, describing a prevalence of 4.5% and a relatively high rate of malignancy (13%). However, it was estimated that the overall prevalence was underestimated and the frequency of malignancy overestimated because of publication bias....